Article

Ruxolitinib acts as a selective inhibitor of CaMKII-γ to impede the progression of Bortezomib-resistant multiple myeloma through AMPK-ULK1 axis-mediated autophagy pathway

2025-10-10

Abstract excerpt

<title>Abstract</title> <p>Multiple myeloma (MM) has become the second most common hematologic malignancy. In recent years, the incidence rate of MM is increasing and the onset age of MM is ahead. Although proteasome inhibitors and other strategies play important roles in the treatment of MM, almost all patients develop resistance after treatment. Therefore, novel drug targets and innovative therapeutic strategie...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fd11088d-786d-577d-b886-d58ef197f73d
DOI: 10.21203/rs.3.rs-7490141/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ruxolitinib acts as a selective inhibitor of CaMKII-γ to impede the progression of Bortezomib-resistant multiple myeloma through AMPK-ULK1 axis-mediated autophagy pathwayDOI 10.21203/rs.3.rs-7490141/v1Read

Unc-51 Like Kinase 3 (ULK3) is essential for autophagy and cell survival in multiple myelomaSemantic proximity Read

NCX1/Ca2+ promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFκB signaling pathwaySemantic proximity Read

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read

Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapySemantic proximity Read

Small-molecule HDAC and Akt Inhibitors Suppress Tumor Growth and Enhance Immunotherapy in Multiple MyelomaSemantic proximity Read

Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signalingSemantic proximity Read

Synergistic Mechanisms of Traditional Chinese Medicine and Proteasome Inhibitors in Multiple Myeloma Therapy: A Comprehensive ReviewSemantic proximity Read

MIR145-3ppromotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targetingHDAC4Semantic proximity Read

NCAPD2 inhibits autophagy by regulating Ca2+/CAMKK2/AMPK/mTORC1 pathway and PARP-1/SIRT1 axis to promote colorectal cancerSemantic proximity Read

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myelomaSemantic proximity Read

CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.Semantic proximity Read

Metformin-Mediated Modulation of the AMPK/mTOR Axis in Hashimoto’s Thyroiditis: A Network Pharmacology and Molecular Docking InvestigationSemantic proximity Read